joined the laboratory of Zanvil Cohn and James Hirsch at Rockefeller University in 1966 to study the control of cellspecific functions by the recently described method of somatic cell hybridization, pioneered by Henry Harris and John Watkins at Oxford (Figure 1 ).
History of Discovery

I
joined the laboratory of Zanvil Cohn and James Hirsch at Rockefeller University in 1966 to study the control of cellspecific functions by the recently described method of somatic cell hybridization, pioneered by Henry Harris and John Watkins at Oxford ( Figure 1 ). 1 I chose to fuse mouse macrophages and melanoma cells using macrophage-restricted markers such as Fc phagocytic receptors and lysozyme secretion. While plasma membrane glycoproteins became rapidly mixed and quiescent macrophage nuclei initiated DNA synthesis when placed within melanoma cell cytoplasm, the macrophage-specific markers were extinguished by unknown mechanisms. Appropriate methods were not available to study heterokaryons by single-cell analysis, so I abandoned somatic cell genetics to study the specific properties of macrophages for their own sake, my research focus until the present day. The striking difference in the secretion of plasminogen activator (urokinase) by inflammatory and resident peritoneal macrophages alerted me to the heterogeneity of resting and newly recruited macrophages, 2 later confirmed by in situ hybridization of lysozyme gene expression in bacille calmette guerin-induced liver granuloma macrophages, compared with Kupffer cells. 3 After moving to the Dunn School in Oxford in 1976, the demonstration by Cesar Milstein and others that cell-specific traits could be captured and immortalized by fusing resting and proliferating cells of like specificity, the basis of directed monoclonal antibody (mAb), made it logical to apply hybridization technology to produce mAb as new markers for mouse macrophages in vivo and in vitro. The F4/80 antibody, isolated by Austyn and Gordon 4 and used by Hume et al to detect F4/80+ macrophages in mouse tissues, 5 revealed morphologically heterogeneous cells in lympho-hematopoietic and other tissues, from early development to adult, in a range of disease models. 6 This plasma membrane antigen was remarkably stable to fixation, providing an efficient marker to detect macrophage processes in brain (microglia) and skin (Langerhans cells), for example. The F4/80 antigen is expressed in subpopulations of dendritic cells, but not on osteoclasts. It is not uniformly expressed by monocyte or macrophage populations, unlike the pan-macrophage intracellular marker, CD68.
The ability to isolate F4/80+ cells from mouse bone marrow enabled Crocker et al 7 to detect new properties of stromal macrophages, such as the ability to bind unopsonized sheep erythrocytes. He developed mAb that blocked this sialic acid-dependent receptor (sialoadhesin, the founding member of the Siglec adhesion receptor family), providing further evidence for heterogeneity among cells of the mononuclear phagocyte family; metallophilic macrophages in the marginal zone of spleen express high levels of sialoadhesin (CD169), but are F4/80 negative. The function of this enigmatic cell type, also found in the subcapsular sinus of lymph nodes, has been studied extensively by den Haan and Kraal. 8 Further mAbs were directed at adhesion molecules of macrophages in cell culture. 9 Hugh Rosen isolated the antiadhesive 5C6 antibody that blocked myeloid cell recruitment in vivo and was found to detect CD11b/18, the type 3 complement receptor; its expression profile in vivo was markedly heterogeneous, dim on alveolar macrophages and Kupffer cells, but highly expressed on microglia, as well as neutrophils. We then repeated the antiadhesion screen using a different culture substrate. The 2F8 antibody blocked EDTA-resistant adhesion to serum-coated tissue culture plastic, and turned out to be directed against the class A type I/II scavenger receptor, implicated in foam cell formation. 10, 11 These nonopsonic, endocytic/phagocytic receptor reagents were followed by the development of mAb against the mannose receptor (CD206), introduced to our laboratory by a sabbatical visitor, Stahl and Gordon 12 and exploited by Martínez-Pomares et al to detect distinct ligands for its carbohydrate binding and cysteine-rich domains in endocrine as well as lymphoid and other tissues. 13 Brown and colleagues used expression cloning with unopsonized
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Siamon Gordon zymosan particles as screen to identify the -glucan receptor, Dectin-1; with the help of collaborators he produced mAb directed against this and other lectins, Dectin-2 and myeloid inhibitory C-type-lectin-like receptor (CLEC 12 A), and immunocytochemical studies reinforced our appreciation of macrophage heterogeneity among tissue macrophages. 14 Molecular cloning of the F4/80 antigen by Andrew McKnight identified it as a 7-transmembrane G-protein-coupled receptor, part of an epidermal growth factor-module-containing mucin-like hormone receptor-like-2 family. 6 Its function proved elusive until Joan Stein Streilein showed that F4/80-deficient mice, produced by Lin et al, were unable to develop peripheral immune tolerance in the anterior chamber of the eye. 15 Its ligand(s) and signaling mechanisms remain obscure. Another mAb, 7/4, isolated initially by Hirsch and Gordon, 16 but only characterized by Philip Taylor more than 20 years later as a member of the LY6 family, was highly expressed on polymorphonuclear leukocytes, but dimly on monocytes and subsets of activated granuloma macrophages. 17 With the aid of these reagents, we were in a position to characterize the effects of cytokines on different macrophage populations in vitro, as well as in situ. Naturally occurring macrophage colony-stimulating factor-deficient osteopetrotic mice were deficient in some F4/80+ macrophage populations, while retaining others. Interferon- was a potent, selective downregulator of the macrophage mannose receptor, whereas interleukin-4 treatment by Stein et al, and subsequently interleukin-13, enhanced its expression. 18 These observations gave rise to the concept of an alternative, T helper 2-dependent pathway of macrophage activation. Studies by Mukhopadyay et al revealed that another class A scavenger receptor, MARCO, is an excellent macrophage-restricted marker of innate, Toll-like receptor-regulated activation. 19 Coming full circle, before closing my laboratory, Laura Helming and I returned to the question of macrophage fusion, using mAb to identify surface molecules implicated in homokaryon formation. She identified CD36, a class B scavenger receptor, as 1 of several molecules involved in macrophage fusion induced by interleukin-4 in alternatively activated macrophages.
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Macrophage Heterogeneity and Vascular Biology
My interest in the role of monocytes and macrophages in the vascular system was stimulated by Russell Ross, who appreciated that atherosclerosis is a modified form of inflammation, and by Monty Krieger and Tat Kodama who characterized the molecular cell biology of scavenger receptor A(I/II) (SR-A) (Figure 2 ). Studies by de Villiers et al showed that macrophage colonystimulating factor upregulated its expression in macrophages, 21 and that the antigen was readily detected in foamy macrophages in experimental atherosclerosis. CD68 was also an excellent marker for lipid-laden macrophages. The unrelated SR, CD163 has been shown to detect an interleukin-10 and glucocorticoidregulated subpopulation of macrophages in lesions. Recent studies by Neyen et al demonstrated that natural ligands of SR-A include apolipoproteins A1 and E. 22 The SR-A was dormant in resting microglia, although expressed, together with other endocytic receptors, in perivascular macrophages; Perry et al demonstrated upregulation of SR-A by local endotoxin activation of microglia. These studies extended earlier studies with F4/80 on macrophage heterogeneity in the central and peripheral nervous system. 23 Finally, immune complex-dependent autoimmune glomerulonephritis depends not only on FcR, but also on mannose receptor, expressed by mesangial cells and macrophages. 24 Intriguingly, F4/80+ macrophages are absent in the glomerular tuft in uninflamed kidney, 25 while lining Bowman's capsule, and are present in close proximity to the juxtaglomerular complex, suggestive of a physiological role for macrophages in the regulation of erythropoietin and the generation of renin.
F4/80 expression is a useful marker of sinus-lining macrophages in liver, adrenal and pituitary glands, distinct from true endothelial cells that lack F4/80, while expressing mannose receptor and SR-A, consistent with efficient clearance of ligands from the circulation. Macrophages are also associated with lymphatic vessels. 
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The panel of mAb generated in our laboratory and by collaborators aroused our interest in the heterogeneity of macrophages and their close relatives, dendritic cells and osteoclasts. It demonstrated the importance of unique local tissue microenvironments in determining the phenotype and presumably specialized functions of resident and newly recruited macrophages in organs such as brain, gut, lung, and hematopoietic tissues, during development and in the adult host. Extensive studies on normal and genetically modified laboratory mice and in a range of disease models led to new research questions concerning the versatile roles of macrophages and related cells in homeostasis, immunity, infections, metabolic diseases, and malignancy. Contemporary research into monocyte and macrophage heterogeneity has been markedly stimulated by the experiments of Geissmann et al with fractalkine receptor transgenic mice, 26 the demonstration of patrolling monocytes that do not contribute to recruitment of tissues, 27 and work by Ziegler-Heitbrock and others on human monocyte heterogeneity. 28 Randolph and colleagues, 29 and Libby and colleagues, 30 and their collaborators have used intravital labeling and imaging to delineate the entry and fate of monocytes in vascular and other compartments. Fisher and colleagues have demonstrated targeting of macrophages via SR-A, 31 and Leuschner et al have developed new methods to deliver therapeutic small interfering RNA to macrophages within the living host. 32 These approaches hold out the prospect of selective regulation of macrophage subpopulations, in infection, cancer, and atherosclerosis.
However, we still lack basic knowledge of the bulk of macrophages in different tissues, especially in humans. Current efforts by Leuschner et al, 32 Helming, 20 Martinez Estrada 33 and our collaborators use microarrays, proteomics, and system biology to extend our database on macrophage signatures from different tissue microenvironments in healthy and diseased hosts, both human and mouse. The story I have traced should illustrate how the development of each new method adds an additional layer of complexity, and that much remains to be done to understand the mechanisms by which macrophages achieve the remarkable ability to regulate their gene expression and biosynthesis differentially, appropriate to need. 
